European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...

Behavioral therapy may help children and adults with ADHD manage and change behaviors that are causing them difficulties and stress. In adults, it may also help manage co-occurring conditions like ...

The biotech company is able to genetically modify immune cells, making them capable of attacking tumors directly inside the ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

attacks. plus, what a new cnn poll reveals about how americans feel about trump's handling of the war. >> ignition and liftoff. go to space. go, nasa crew. ten. >> the days turned into weeks. the ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with a left ventricular ejection fraction (LVEF) of ≥40%.